• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 14, 2023 at 09:42: AM
via The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumors.

article source
 

<



Similar threads

cafead
FDA starts speedy review of Servier&#039;s Tibsovo in MDS
Replies
0
Views
223
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts speedy review of Enhertu in lung cancer
Replies
0
Views
198
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eli Lilly kick-starts speedy FDA review for Alzheimer&#039;s hopeful donanemab—and a...
Replies
0
Views
151
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Replies
0
Views
163
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib
Replies
0
Views
203
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote